Lenz Therapeutics, Inc. (LENZ) — 8-K Filings

8-K Filings (18)

• LENZ Therapeutics Reports Q4 2025 Financial Results — Mar 24, 2026
  LENZ Therapeutics, Inc. filed an 8-K on March 24, 2026, under Item 2.02, indicating they are reporting "Results of Operations and Financial Condition." This fil
• 8-K Filing — Dec 12, 2025
• LENZ Therapeutics Files 8-K — Oct 8, 2025 Risk: medium
  LENZ Therapeutics, Inc. filed an 8-K on October 8, 2025, reporting an "Other Event." The filing does not contain specific details about the event itself, but it
• LENZ Therapeutics Files 8-K with Financials — Sep 30, 2025 Risk: low
  On September 30, 2025, LENZ Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update
• LENZ Therapeutics (Formerly Graphite Bio) Files 8-K — Jul 31, 2025 Risk: low
  On July 31, 2025, LENZ Therapeutics, Inc. filed an 8-K report. The filing indicates the company's former names were Graphite Bio, Inc. and Integral Medicines, I
• LENZ Therapeutics Files 8-K on Shareholder Vote Matters — Jun 10, 2025 Risk: low
  On June 10, 2025, LENZ Therapeutics, Inc. filed an 8-K to report on the submission of matters to a vote of security holders. The filing indicates that the compa
• Amgen Acquires LENZ Therapeutics for $3.7 Billion — Apr 15, 2025 Risk: low
  LENZ Therapeutics, Inc. announced on April 15, 2025, that it has entered into a definitive agreement to be acquired by Amgen Inc. for $3.7 billion in cash. This
• LENZ Therapeutics Files 8-K: Material Agreement & Exhibits — Apr 4, 2025 Risk: medium
  On April 4, 2025, LENZ Therapeutics, Inc. filed an 8-K report. The filing indicates an entry into a material definitive agreement and includes financial stateme
• LENZ Therapeutics Files 8-K — Oct 28, 2024 Risk: low
  LENZ Therapeutics, Inc. filed an 8-K on October 28, 2024, reporting other events and financial statements. The company, formerly known as Graphite Bio, Inc. and
• LENZ Therapeutics Files 8-K on Operations — Aug 14, 2024 Risk: low
  LENZ Therapeutics, Inc. filed an 8-K on August 14, 2024, reporting on its results of operations and financial condition. The filing includes financial statement
• LENZ Therapeutics (fka Graphite Bio) Files 8-K — Aug 12, 2024 Risk: low
  On August 12, 2024, LENZ Therapeutics, Inc. filed an 8-K report. The filing indicates that the company was formerly known as Graphite Bio, Inc. and Integral Med
• LENZ Therapeutics Files 8-K: Material Agreement & Equity Sales — Jul 15, 2024 Risk: medium
  On July 14, 2024, LENZ Therapeutics, Inc. filed an 8-K report detailing a material definitive agreement. The company, formerly known as Graphite Bio, Inc. and I
• LENZ Therapeutics Files 8-K — Apr 3, 2024 Risk: low
  LENZ Therapeutics, Inc. filed an 8-K on April 3, 2024, to report other events and financial statements. The company, formerly known as Graphite Bio, Inc. and In
• LENZ Therapeutics Files 8-K: Acquisition, Equity Sales, and Control Changes — Mar 22, 2024 Risk: medium
  On March 21, 2024, LENZ Therapeutics, Inc. (formerly Graphite Bio, Inc.) filed an 8-K detailing several significant events. These include the completion of an a
• Graphite Bio Files 8-K Report — Mar 19, 2024 Risk: low
  On March 19, 2024, Graphite Bio, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, and includes a Regulation FD Disclos
• Graphite Bio Files 8-K on Shareholder Votes and Financials — Mar 14, 2024 Risk: low
  On March 14, 2024, Graphite Bio, Inc. filed an 8-K report detailing the submission of matters to a vote of security holders and financial statements. The compan
• Graphite Bio Files 8-K for Regulatory Disclosures — Mar 8, 2024 Risk: low
  Graphite Bio, Inc. filed an 8-K on March 8, 2024, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as
• Graphite Bio Appoints New Chief Medical Officer — Mar 5, 2024 Risk: medium
  On March 5, 2024, Graphite Bio, Inc. announced the appointment of Dr. Joshua Grass as Chief Medical Officer. Dr. Grass brings extensive experience in clinical d

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX